Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2003

View Archived Issues

Novel protein kinase inhibitors in early development at Aventis

Pfizer claims new GlyT-1 inhibitors for psychosis and other disorders

New antiprotozoal protein kinase inhibitors identified by Merck researchers

Increased survival associated with antitumor T-cell response in ovarian cancer

Effective dose of darbepoetin alfa for increasing preoperative hemoglobin levels

No significant effects reported for celecoxib on fracture healing in rats

Atazanavir reported safe and effective in reducing HIV infection

Takeda designs new antidiabetic agents

Recent patent reports novel PDE4 inhibitors with utility in asthma and other disorders

Kissei scientists design new series of SGLT-2 inhibitors

Bayer patent covers thiazole-based agents for HSV

Antiparkinsonian agents with novel mechanism of action

Novel PLA2 inhibitors discovered by Nippon Soda scientists

ATL-1102 cleared to enter clinical trials

Preoperative epoetin alfa reduces blood transfusion requirement in knee or hip arthroplasty

AstraZeneca files European MAA for Faslodex in advanced breast cancer

Vical to develop DNA vaccine against CMV

Serono's Raptiva marketing rights extended to Asia

Boehringer Ingelheim initiates phase III RESIST program for tipranavir

Medtronic to exclusively market rhBMP-2 in Europe

Cerus begins phase I trial of EBV vaccine

Access program launched for cetuximab

Preclinical anti-HIV development candidate presented at medicinal chemistry conference

Design and synthesis of potent and selective direct thrombin inhibitors

LY-355703 associated with peripheral neuropathy and myalgia in early clinical studies

New inhibitors of iNOS with oral antiinflammatory activity identified at AstraZeneca

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...